

MEDICAL ADVISOR

Dr. Daniel Laskowitz (https://neurology.duke.edu/faculty/daniel-todd-laskowitz) serves as Director of Neurosciences Medicine at the Duke Clinical Research Institute as well as Professor and Vice Chair of Neurology, Professor of Anesthesiology and Neurobiology, and Director of Neurovascular Laboratories at Duke University School of Medicine. Dr. Laskowitz's research focuses on the identification of new therapies for the treatment of stroke and acute brain injury. He operates a neuroscience translational laboratory, which uses molecular biology and transgenic technology to evaluate the cellular mechanism of brain injury and secondary neuronal injury. These results are translated to clinically-relevant small animal models with the ultimate goal of exploring new therapeutic interventions in the clinical setting of cerebral ischemia, intracranial hemorrhage, and closed head injury. Dr. Laskowitz's translational research also focuses on the use of biomarkers, both to investigate cellular mechanisms of post-traumatic neurodegeneration and to provide diagnostic and clinical information in the setting of ischemic and traumatic brain injury. Dr. Laskowitz has designed one of the first multicenter trials evaluating the role of serum biomarkers in stroke (the BRAIN study), and the first translational study evaluating the uses of statins in subarachnoid hemorrhage. He has served as the site PI for a number of trials in stroke and acute brain injury, including SOCRATES, COBIS, SyNAPSe, and ACTION. He is a fellow of the American Heart Association, American Academy of Neurology, and the American Neurological Association, and has authored and co-authored more than 170 peerreviewed articles. Dr. Laskowitz is a graduate of Duke University School of Medicine (1991) and Brown University (1987), where he majored in neuroscience. After completing his Neurology Residency at the University of Pennsylvania in 1995, he returned to Duke to complete fellowship training in Neurocritical care and Stroke. He has remained active in both laboratory-based and clinical research and completed his Master's of Health Science in 2003.